5.	Investment in Limited Liability Company

August 8, 2017,

the Company entered into an exclusive Distributorship Agreement (the “Distributorship Agreement”) with InControl Medical, LLC (“ICM”), a Wisconsin limited liability company focused on women's health, pursuant to which the Company will directly market, promote, distribute and sell ICM's products to licensed medical professional offices and hospitals in North America.

Under the terms of the Distributorship Agreement, ICM agreed to

not

directly or indirectly appoint or authorize any

third

party to market, promote, distribute or sell any of the licensed products to any licensed medical professional offices and hospitals in the United States. In exchange, the Company agreed to

not

market, promote, distribute or sell (or contract to do so) any product which substantially replicates all or almost all of the key features of the licensed products. The terms of the Distribution Agreement also included a minimum purchase requirement to purchase a certain quantity of ICM products per month. In addition, the parties agreed to certain mutual marketing obligations to promote sales of the licensed products. During the years ended

December 31, 2020

and

2019,

the Company has purchased

485

and

300

units of ICM products for approximately

$51,000

and

$26,000

and, respectively. The Company paid ICM approximately

$52,000

and

$27,000

for product related costs during the years ended

December 31, 2020

and

2019,

respectively. There were

amounts due to ICM for accounts payable as of

December 31, 2020

and

2019.

In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested

$2,500,000

in, and acquired membership units of, ICM. This investment has been recorded in investment in a limited liability company in the consolidated balance sheets. The Company used the equity method to account for the investment in ICM because the Company does

not

control it but has the ability to exercise significant influence over it. As of

December 31, 2020,

the Company owns approximately

ownership interest in ICM. The Company recognizes its allocated portion of ICM's results of operations on a

three

-month lag due to the timing of financial information. For the years ended

December 31, 2020

and

2019,

the allocated net loss from ICM's operations was

$383,000

and

$627,000,

respectively. The allocated net loss from ICM's operations was recorded as a loss from minority interest in limited liability company in the consolidated statements of operations.

February 2019,

the Company executed a mutual termination of the Distributorship Agreement with ICM. As a result, the Company

longer has a minimum purchase requirement to purchase a certain quantity of ICM products per month.